Mucosal lesions in cutaneous lupus erythematosus successfully treated with hydroxychloroquine

Kamaguchi, Mayumi; Iwata, Hiroaki; Asaka, Takuya; Shimizu, Hiroshi; Kitagawa, Yoshimasa

doi:10.1002/osi2.1006


Hokkaido University \| Library \| HUSCAP	Advanced Search		言語

	Home
	About HUSCAP
	Open Access Policy

	Browse by Author

Browse
	Communities & Collections

	Scholarly Journals
	Theses
	Doctoral Dissertations Listed by Graduate Schools
	Conference Procs.
	Events

	HUSCAP Senior (in Japanese)

	Societies

	Downloads (country)

For university staff
	How to post your papers to HUSCAP
	Publication of theses
	Helpline about theses publication

Open Archives Compliant

You can search our collection also at:
	Google
	Google Scholar
	CiNii
	IRDB
	OAIster
	NDLTD

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Mucosal lesions in cutaneous lupus erythematosus successfully treated with hydroxychloroquine

This item is licensed under:Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International

Files in This Item:

Oral sci int_16_106.pdf

1.92 MB

PDF

View/Open

Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/79020

Title:	Mucosal lesions in cutaneous lupus erythematosus successfully treated with hydroxychloroquine
Authors:	Kamaguchi, Mayumi Browse this author
	Iwata, Hiroaki Browse this author →KAKEN DB
	Asaka, Takuya Browse this author →KAKEN DB
	Shimizu, Hiroshi Browse this author →KAKEN DB
	Kitagawa, Yoshimasa Browse this author →KAKEN DB
Keywords:	cutaneous lupus erythematosus
	hydroxychloroquine
	mucosal lesion
Issue Date:	Aug-2019
Publisher:	John Wiley & Sons
Journal Title:	Oral science international
Volume:	16
Issue:	2
Start Page:	106
End Page:	109
Publisher DOI:	10.1002/osi2.1006
Abstract:	Cutaneous lupus erythematosus (CLE) is a rare, potentially disfiguring, chronic autoimmune disease with extremely variable skin and mucosal membrane manifestations. Hydroxychloroquine (HCQ) is an antimalarial drug that has been used in various countries to treat autoimmune diseases including CLE. HCQ was banned for a long time in Japan because of severe chloroquine retinopathy and was reapproved as a first-line treatment for CLE in 2015. There are no case reports describing the effectiveness of HCQ for CLE with oral mucosal lesions in the dental field. We present a case of CLE whose oral lesions were successfully treated with HCQ.
Rights:	© 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Rights:	http://creativecommons.org/licenses/by-nc-nd/4.0/
Type:	article (author version)
URI:	http://hdl.handle.net/2115/79020
Appears in Collections:	北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 岩田浩明

OAI-PMH ( junii2 , jpcoar_1.0 )

- Hokkaido University